The text includes unaudited consolidated financial statements of Boston Scientific Corporation and its subsidiaries for the three and nine months ended September 30. It displays information like net sales, costs, gross profit, operating expenses, balance sheets, comprehensive income, stockholders' equity, and cash flows, showcasing the company's performance metrics regarding revenue, expenses, profits, and financial data during these periods. In addition to financial data, it elaborates on hedging relationships, fair value measurements, and financial assets and liabilities, offering details on reclassification of amounts from AOCI into earnings, net gains on derivative instruments, fair value measurements, and the Level 1, Level 2, and Level 3 fair value hierarchy components. The discussion further delves into the fair value assessments of financial assets and liabilities, changes in fair value, and financing arrangements of the company.
Boston Scientific Corporation is a global medical device company facing challenges and opportunities. The impact of the COVID-19 pandemic on operations and financial performance has been significant, including delays in procedures and global sales challenges. However, the company has seen a recovery in sales trends as restrictions ease in some regions. Ensuring the health and safety of patients, healthcare providers, and employees remains a top priority for Boston Scientific. Additionally, the company is committed to corporate sustainability, with initiatives aligned with the United Nations Sustainable Development Goals. Boston Scientific aims to achieve carbon neutrality in manufacturing and distribution sites by 2030 and transition to renewable energy sources by 2024. Financially, there was an increase in net sales driven by the recovery of elective and semi-emergent procedure volumes. Adjusted net income for the third quarter of 2021 was $581 million, demonstrating the company's resilience and ability to adapt in challenging global circumstances. Moreover, the text discusses a recent divestiture, efforts to expand in Emerging Markets, and factors influencing gross profit margins and operating expenses, providing a comprehensive overview of Boston Scientific's current status and future aspirations.
The company operates globally in the medical devices industry, facing market risks from currency exchange rate and interest rate fluctuations. They use derivative financial instruments to manage these risks in line with corporate risk management policies, aiming to offset gains and losses effectively. Currency risk stems from foreign currency exposure in firm commitments and intercompany transactions, while interest rate risk is mitigated through U.S. dollar borrowings and cash investments. Derivative instruments help manage earnings and cash flow amidst these risks, with further details provided in the financial statements.
The text discusses the evaluation of disclosure controls and procedures by the management, including the CEO and CFO, as of September 30, 2021. The evaluation was conducted in accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934, and the CEO and CFO concluded that the disclosure controls and procedures were effective. Additionally, it mentions that there were no material changes observed in the internal control over financial reporting in the third quarter of 2021, despite employees working remotely due to COVID-19 restrictions. The company had been using electronic tools to facilitate financial reporting processes even before the pandemic, and the transition to remote work did not significantly affect their internal controls and procedures.
The text provided references legal proceedings and directs the reader to refer to specific sections, Note G - Income Taxes and Note H - Commitments and Contingencies, within the unaudited consolidated financial statements found in Item 1 of the Quarterly Report on Form 10-Q. It indicates that these sections are incorporated by reference for further details on legal proceedings.
Consider the risk factors outlined in Part I, Item 1A of the most recent Annual Report filed on Form 10-K, in addition to other information in the report, as they could significantly impact the company's business, financial status, and future outcomes.
I am ready to help summarize the text once you share it with me.
I am ready to summarize the text. Please provide the text that you would like me to summarize.
I am ready to summarize the text for you. Please go ahead and provide me with the text you would like me to summarize.
I am ready to summarize the text. Please go ahead and provide the text for me to summarize.
The text consists of a list of exhibits filed with a report by Boston Scientific Corporation. It includes details about a Second Supplemental Indenture, certifications by the Chief Executive Officer and Chief Financial Officer under the Sarbanes-Oxley Act of 2002, and various XBRL Taxonomy Extension documents. The document is signed by Daniel J. Brennan, the Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, on November 4, 2021.
